Showing results (411-420 of 425) with videos related to
Sort By:
Pageof 43
Cell Reports|October 16, 2022
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two dosesAlexandra Tauzin, Shang Yu Gong, Debashree Chatterjee, et al.American Heart Journal|February 23, 2021
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trialZhen Ge, Xiao-Fei Gao, Jing Kan, et al.Cell Reports|June 22, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.Cell Host & Microbe|June 16, 2021
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responsesAlexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.Biorxiv : the Preprint Server for Biology|March 24, 2021
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesAlexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.American Heart Journal|June 28, 2024
PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN studyZhi-Ming Wu, Jing Kan, Fei Ye, et al.Cell Host & Microbe|December 26, 2021
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between dosesAlexandra Tauzin, Shang Yu Gong, Guillaume Beaudoin-Bussières, et al.Journal of Clinical Immunology|August 10, 2022
Cryptococcus gattii Infection as the Major Clinical Manifestation in Patients with Autoantibodies Against Granulocyte-Macrophage Colony-Stimulating FactorShang-Yu Wang, Yu-Fang Lo, Han-Po Shih, et al.Medicine|June 24, 2016
Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infectionsChih-Yu Chi, Chia-Hao Lin, Mao-Wang Ho, et al.Science Immunology|May 9, 2025
Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-γJhan-Jie Peng, Jing-Ya Ding, Yingxi Xu, et al.Pageof 43